<DOC>
	<DOCNO>NCT00485160</DOCNO>
	<brief_summary>The purpose study determine whether closure PDA premature neonates use IV ibuprofen v continuous IV indomethacin different side effect , eg . effect renal function , blood flow velocity superior mesenteric artery , anterior cerebral artery , renal artery .</brief_summary>
	<brief_title>Ibuprofen v . Continuous Indomethacin Treatment PDA</brief_title>
	<detailed_description>Despite fact ibuprofen appear minimize renal side effect see follow bolus indomethacin , concern regard short long-term safety remain . Indomethacin , hand , use treat premature neonates many year . Other transient vasoconstrictive effect , significant toxicity note . Thus , able eliminate differential renal effect , indomethacin would remain , many , therapy choice premature neonate persistent PDA . We hypothesize continuous administration indomethacin would provide option . Ibuprofen therapy , date , compare indomethacin administer continuous infusion . Hence , current study attempt determine whether continuous indomethacin administration could potentially offer advantage ibuprofen treat PDA , specifically term mitigation renal side effect . Specifically , primary objective show difference urine output and/or serum creatinine treatment group . As secondary objective , aim show potentially vascular-mediated clinical difference , eg . Necrotizing enterocolitis ( NEC ) , intraventricular hemorrhage ( IVH ) , retinopathy prematurity ( ROP ) bilirubin albumin bind group . B-type natriuretic peptide ( BNP ) release ventricular myocytes response ventricular volume load . It , turn , mediate vasodilation , natriuresis diuresis . Serum BNP level show clinically useful differentiate respiratory cardiac disease , monitor heart failure therapy serve early diagnostic biomarkers ductal patency premature neonates . As secondary objective intend determine whether decrease BNP level would equally reliable indicator therapeutic efficacy infant treat ibuprofen indomethacin.In addition look comparative effect vascular bed might mediate long term side effect describe .</detailed_description>
	<mesh_term>Ductus Arteriosus , Patent</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>&lt; 1500 gm birth weight PDA confirm echocardiography Additional congenital heart lesion Significant congenital malformation Documented infection Thrombocytopenia ( &lt; 60,000 ) IVH grade 4</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Weeks</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Patent Ductus Arteriosus</keyword>
	<keyword>Indomethacin</keyword>
	<keyword>Ibuprofen</keyword>
	<keyword>Renal effect</keyword>
</DOC>